% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brinkmann:290535,
      author       = {B. J. Brinkmann and A. Floerchinger and C. Schniederjohann
                      and T. Roider and M. Coelho and N. Mack$^*$ and P.-M. Bruch
                      and N. Liebers and S. Dötsch and D. H. Busch and M.
                      Schmitt$^*$ and F. Neumann and P. M. Roessner$^*$ and M.
                      Seiffert$^*$ and S. Dietrich},
      title        = {{CD}20-bispecific antibodies improve response to
                      {CD}19-{CAR} {T}-cells in lymphoma in-vitro and {CLL}
                      in-vivo models.},
      journal      = {Blood},
      volume       = {144},
      number       = {7},
      issn         = {0006-4971},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2024-01152},
      pages        = {784-789},
      year         = {2024},
      note         = {2024 Aug 15;144(7):784-789},
      abstract     = {Anti-CD19 chimeric antigen receptor T-cells (CD19-CAR)
                      represent an effective treatment for relapsed/refractory
                      B-cell malignancies but incomplete responses often result in
                      early disease progression. We here assessed potential
                      benefits of co-administering CD20-targeting bispecific
                      antibodies (CD20-BsAb) with CD19-CAR, aiming to enhance
                      immunotherapeutic efficacy. Addition of CD20-BsAb to
                      co-cultures of CD19-CAR and primary samples of B-cell
                      malignancies, comprising malignant B- and endogenous
                      T-cells, significantly improved killing of malignant cells
                      alongside enhanced expansion of both endogenous T-cells and
                      CD19-CAR. CD20-BsAb induced an increase in proliferation and
                      activation of endogenous T-cells and CD19-CAR. In an
                      immunocompetent mouse model of CLL, relapse after initial
                      treatment response frequently occurred after CD19-CAR
                      monotherapy. Combination with injections of CD20-BsAb
                      significantly enhanced treatment response and resulted in
                      improved eradication of malignant cells. Higher efficacy was
                      accompanied by improved T-cell expansion upon CD20-BsAb
                      administration and resulted in longer survival, with $80\%$
                      of mice being cured with no detectable malignant cell
                      population within eight weeks of therapy initiation.
                      Collectively, our in-vitro and in-vivo data demonstrate
                      enhanced therapeutic efficacy of CD19-CAR when combined with
                      CD20-BsAb in B-cell malignancies. Activation and
                      proliferation of both infused CAR T-cells as well as
                      endogenous T-cells may contribute to improved disease
                      control.},
      cin          = {B062 / B060 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)B060-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38805637},
      doi          = {10.1182/blood.2023022682},
      url          = {https://inrepo02.dkfz.de/record/290535},
}